B

Braeburn

Develops next-generation OUD medications with counseling

Key Account Manager

Full-Time
No salary listed
Senior
Bachelor's, Master's
Boston, MA, USA
RemoteWillingness to travel regionally and nationally; some territories may require overnight travel up to 50–70%.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A bachelor's degree (BS/BA) is required; an advanced business degree is a plus.
  • At least 7 years of pharmaceutical experience, including at least 3 years of sales and/or field market access experience in biotech, specialty pharmaceutical, or device industries.
  • Demonstrated sales or field market access performance in Specialty Pharmacy markets, supported by market performance reports and recognition awards.
  • In-depth understanding of reimbursement and insurance coverage for physician-administered treatments.
  • Proven product launch experience in a highly complicated and competitive environment.
  • Experience selling specialty products, particularly physician-administered products such as implantable or injectable medication technologies in a healthcare setting.
  • Ability to work autonomously to find new business opportunities.
  • A valid driver's license in good standing.
  • Experience within a complex distribution model, including Specialty Pharmacy, Buy & Bill, and direct distribution.
  • Proven expertise informing healthcare provider offices about coding, billing, and submissions across payer environments.
  • Ability to build relationships and inform healthcare professionals about products.
  • Ability to solve problems and demonstrate strong attention to detail and follow-through.
  • Commitment to ethical behavior, compliance, accountability, ownership, and improving addiction and mental health patient care.
  • Willingness to travel regionally and nationally; some territories may require overnight travel up to 50–70%.
Responsibilities
  • Achieve planned Braeburn goals, patient access objectives, and other performance measures for the assigned geography.
  • Review, analyze, and interpret reports, facts, and data to plan and execute territory activities that meet quarterly and annual objectives.
  • Develop a deep understanding of the assigned territory, including care delivery, major payers, regulatory environment, industry trends, emerging competition, reimbursement patterns, and state laws and policies.
  • Master disease-state and product information and communicate it compliantly in accordance with FDA-approved product labeling and the REMS program.
  • Prepare for sales calls by engaging account personnel, uncovering needs and opportunities, communicating approved solutions, addressing customer concerns, gaining advance commitment, and completing post-call analysis and next steps.
  • Use internally approved materials to inform physicians and office personnel about access information for Braeburn products.
  • Manage and support accounts, ensure product access, and resolve or triage reimbursement issues in compliance with company policies and procedures to optimize customer and patient experience.
  • Collaborate with cross-functional partners and maintain ongoing dialogue with customers to anticipate and adapt to their needs and changing market challenges and opportunities.
  • Exercise sound judgment and ensure compliance with company policies and the Code of Conduct.
  • Exercise fiscal control of operational expenses.
  • Conduct all work activities in accordance with company policies and code of conduct.
Desired Qualifications
  • Experience in a start-up environment.

About the company

Braeburn focuses on developing next-generation medications for opioid use disorder (OUD) and sells these therapies to healthcare providers, clinics, and patients with the aim of supporting recovery. The medicines are intended to be used together with counseling and support services as part of a comprehensive treatment plan for OUD. The company advances its goal through research, development, and commercialization of therapies, often in partnerships with other healthcare organizations, within the regulated pharmaceutical market. Unlike many generic care models, Braeburn emphasizes a mission-driven approach that combines medical treatments with patient support to help individuals reintegrate into their communities. The overall aim is to reduce the opioid crisis by providing effective, accessible treatments that help patients overcome addiction and rebuild their lives.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$266M

Headquarters

Washington DC, District of Columbia

Founded

2012

Get referred to Braeburn

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Braeburn published 2026 CPDD and ASCP data showing withdrawal suppression and retention benefits.
  • Camurus said Brixadi captured roughly 32% of U.S. long-acting buprenorphine units in Q1 2026.
  • September 2026 JSAT safety analysis strengthens Braeburn's postmarketing evidence for prescribers and payers.

What critics are saying

  • Brixadi's intravenous misuse risk triggers REMS restrictions and serious-harm warnings across 2026 labeling.
  • Indivior's Sublocade remains the category leader, limiting Braeburn's pricing power through 2026.
  • Reported Camurus acquisition talks in September 2026 signal Braeburn's standalone future is uncertain.

What makes Braeburn unique

  • Brixadi offers weekly and monthly buprenorphine injections with room-temperature storage, unlike many rivals.
  • Braeburn expanded its U.S. commercial and medical affairs teams during 2026 for Brixadi adoption.
  • Camurus reported Braeburn drove 42% royalty growth in 2026 from U.S. Brixadi uptake.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-1%

2 year growth

-1%
New York Globe
Sep 12th, 2025
Swedish Biotech Camurus in Talks to Buy US-Based Braeburn in $1 Billion Opioid Market Bet

Swedish biotech Camurus in talks to buy New York Globe-based Braeburn in $1 billion opioid market bet.

Braeburn
Sep 30th, 2024
Braeburn Debuts Inspiring Docuseries Celebrating Advocates Uplifting Communities to Combat the Opioid Crisis

(PLYMOUTH MEETING, PA - September 30, 2024) - Braeburn Inc. today announced the launch of Reframe and Reclaim: Shaping the Future of Recovery Stories, a mini docuseries on BraeburnRx.com aimed at destigmatizing opioid use disorder (OUD) and celebrating the compelling advocacy of community champions.

We-Ha.com LLC
Jul 6th, 2023
New Principal Named for West Hartford's Braeburn Elementary School

She will take over for Kim Ambroise, who had served as Braeburn’s interim principal since late 2022, following the departure of the former principal, Jeff Sousa, for a superintendent position in New Hartford.

Cision
May 23rd, 2023
Camurus Announces Fda Approval Of Brixadi™ For The Treatment Of Moderate To Severe Opioid Use Disorder

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder. .

Braeburn
Sep 24th, 2021
Braeburn hires Joshua M. Cohen as Chief Medical Officer

Braeburn announces that Joshua M. Cohen, MD, MPH, FAHS has joined the company as Chief Medical Officer.